.

Make Better Decisions

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
Novartis
Queensland Health
Accenture
AstraZeneca
Colorcon
McKesson
Healthtrust
Express Scripts
Cerilliant

Generated: December 15, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,562,980

« Back to Dashboard

Which drugs does patent 8,562,980 protect, and when does it expire?


Patent 8,562,980 protects ZENPEP and is included in one NDA.

This patent has thirty-three patent family members in twenty-three countries.

Summary for Patent: 8,562,980

Title:Stable digestive enzyme compositions
Abstract: Compositions of the present invention, comprising at least one digestive enzyme (e.g., pancrelipase) are useful for treating or preventing disorders associated with digestive enzyme deficiencies. The compositions of the present invention can comprise a plurality of coated particles, each of which is comprised of a core coated with an enteric coating comprising at least one enteric polymer and 4-10% of at least one alkalinizing agent, or have moisture contents of about 3% or less, water activities of about 0.6 or less, or exhibit a loss of activity of no more than about 15% after six months of accelerated stability testing.
Inventor(s): Ortenzi; Giovanni (Monza, IT), Marconi; Marco (Cinisello Balsamo, IT), Mapelli; Luigi (Milan, IT)
Assignee: Aptalis Pharma Limited (Wicklow, IE)
Application Number:13/019,856
Patent Claim Types:
see list of patent claims
Composition; Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
Forest Labs IncZENPEPpancrelipase (amylase;lipase;protease)CAPSULE, DELAYED RELEASE;ORAL022210-007Mar 25, 2014RXYesNo► Subscribe► Subscribe► SubscribeYTREATMENT OF EXOCRINE PANCREATIC INSUFFICIENCY DUE TO CYSTIC FIBROSIS OR OTHER CONDITIONS
Forest Labs IncZENPEPpancrelipase (amylase;lipase;protease)CAPSULE, DELAYED RELEASE;ORAL022210-005Jun 15, 2011RXYesNo► Subscribe► Subscribe► SubscribeYTREATMENT OF EXOCRINE PANCREATIC INSUFFICIENCY DUE TO CYSTIC FIBROSIS OR OTHER CONDITIONS
Forest Labs IncZENPEPpancrelipase (amylase;lipase;protease)CAPSULE, DELAYED RELEASE;ORAL022210-002Aug 27, 2009RXYesNo► Subscribe► Subscribe► SubscribeYTREATMENT OF EXOCRINE PANCREATIC INSUFFICIENCY DUE TO CYSTIC FIBROSIS OR OTHER CONDITIONS
Forest Labs IncZENPEPpancrelipase (amylase;lipase;protease)CAPSULE, DELAYED RELEASE;ORAL022210-003Aug 27, 2009RXYesNo► Subscribe► Subscribe► SubscribeYTREATMENT OF EXOCRINE PANCREATIC INSUFFICIENCY DUE TO CYSTIC FIBROSIS OR OTHER CONDITIONS
Forest Labs IncZENPEPpancrelipase (amylase;lipase;protease)CAPSULE, DELAYED RELEASE;ORAL022210-001Aug 27, 2009RXYesNo► Subscribe► Subscribe► SubscribeYTREATMENT OF EXOCRINE PANCREATIC INSUFFICIENCY DUE TO CYSTIC FIBROSIS OR OTHER CONDITIONS
Forest Labs IncZENPEPpancrelipase (amylase;lipase;protease)CAPSULE, DELAYED RELEASE;ORAL022210-004Aug 27, 2009RXYesNo► Subscribe► Subscribe► SubscribeYTREATMENT OF EXOCRINE PANCREATIC INSUFFICIENCY DUE TO CYSTIC FIBROSIS OR OTHER CONDITIONS
Forest Labs IncZENPEPpancrelipase (amylase;lipase;protease)CAPSULE, DELAYED RELEASE;ORAL022210-006Jul 13, 2011RXYesYes► Subscribe► Subscribe► SubscribeYTREATMENT OF EXOCRINE PANCREATIC INSUFFICIENCY DUE TO CYSTIC FIBROSIS OR OTHER CONDITIONS
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 8,562,980

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,562,981Stable digestive enzyme compositions► Subscribe
7,658,918Stable digestive enzyme compositions► Subscribe
8,562,979Stable digestive enzyme compositions► Subscribe
8,293,229Methods of producing stable pancreatic enzyme compositions► Subscribe
8,562,978Stable digestive enzyme compositions► Subscribe
8,246,950Stable digestive enzyme compositions► Subscribe
8,221,747Stable pancreatic enzyme compositions► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,562,980

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Taiwan201422233► Subscribe
TaiwanI421090► Subscribe
Taiwan200843795► Subscribe
Singapore186648► Subscribe
Russian Federation2445952► Subscribe
Russian Federation2009135038► Subscribe
Portugal2079445► Subscribe
New Zealand598477► Subscribe
New Zealand579047► Subscribe
Mexico2009008828► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Julphar
US Department of Justice
AstraZeneca
Cantor Fitzgerald
Colorcon
Covington
Boehringer Ingelheim
UBS
Baxter
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot